Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TPST Tempest Therapeutics Inc.

Market Closed 06-12 16:00:00 EDT

1.26

+0.01

+0.80%

盘后1.26

+0.000.00%

16:04 EDT

High1.29	Low1.25	Vol37.77K
Open1.26	D1 Closing1.25	Amplitude2.80%
Mkt Cap18.66M	Tradable Cap12.26M	Total Shares14.81M
T/O47.98K	T/O Rate0.39%	Tradable Shares9.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TPST","market":"US","secType":"STK","nameCN":"Tempest Therapeutics Inc.","latestPrice":1.26,"timestamp":1781294400000,"preClose":1.25,"halted":0,"volume":37769,"hourTrading":{"tag":"盘后","latestPrice":1.26,"preClose":1.26,"latestTime":"16:04 EDT","volume":5,"amount":6.3,"timestamp":1781294688451,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.008000000000000007,"floatShares":9733600,"shares":14806997,"eps":-5.7,"marketStatus":"Market Closed","change":0.01,"latestTime":"06-12 16:00:00 EDT","open":1.26,"high":1.285,"low":1.25,"amount":47982,"amplitude":0.028,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.7,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.25,"preHourTrading":{"tag":"盘前","latestPrice":1.26,"preClose":1.25,"latestTime":"09:22 EDT","volume":159,"amount":201.1018167,"timestamp":1781270537258,"change":0.01,"changeRate":0.008,"amplitude":0.01528},"postHourTrading":{"tag":"盘后","latestPrice":1.26,"preClose":1.26,"latestTime":"16:04 EDT","volume":5,"amount":6.3,"timestamp":1781294688451,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5785656951517708,"impliedVol":1.4125,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TPST/tweets","defaultTab":"tweets","newsList":[{"id":"2642584044","title":"Tempest Therapeutics director William Drake Richey files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642584044","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642584044?lang=en_us&edition=fundamental","pubTime":"2026-06-09 09:01","pubTimestamp":1780966903,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics director William Drake Richey reported 2,000 shares of common stock in an initial Form 3 filing dated June 4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDLqQyft:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641491167","title":"Tempest Therapeutics - Nicholas Maestas Resigns as CFO Effective June 5, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641491167","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641491167?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:01","pubTimestamp":1780606914,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C0LC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641167392","title":"Tempest Therapeutics adds Drake Richey, John Yee to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2641167392","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641167392?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:37","pubTimestamp":1780605446,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics appointed Drake Richey, president of Bush & Company, and John Yee, MD, MPH, SVP medical affairs at Apnimed, to its board.Richey previously led Life Check, worked as a portfolio manager at Wells Fargo, and held a director role at Fitch Ratings.Yee previously served as CMO at Sobi North America, held senior medical affairs roles at Flexion and Vertex, and worked at AstraZeneca.Appointments take effect June 4, 2026; both directors join as independents.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL9HlmTp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0496365809.HKD","LU0058720904.USD","BK5011","IE00B64PRP62.GBP","NAH.UK","LU2355687059.USD","LU0158827948.USD","LU1989772840.SGD","LU0738911758.USD","LU0314104364.USD","LU1880407132.USD","LU0499090636.EUR","LU2089284900.SGD","LU2237443895.HKD","LU0964806797.USD","AZN.UK","LU0784384876.USD","LU2108987350.USD","IE00BN0W2V16.EUR","LU1481599808.USD","LU1267930490.SGD","LU1923622614.USD","LU0963555726.SGD","LU0708994859.HKD","IE0009355771.USD","LU0289739699.SGD","LU2125909247.SGD","LU0029864427.USD","03165","IE00BN0W2T93.GBP","LU1983299246.USD","LU1301847155.USD","LU1267930573.SGD","LU1989772923.USD","LU2091194634.USD","LU0949170772.SGD","NDAQ","TPST","LU0882574055.USD","LU1496350502.SGD","LU0889566641.SGD","LU0310800379.SGD","LU0390134368.USD","LU2095319765.USD","BK4588","LU1989771016.USD","LU0553294199.USD","LU0171293334.USD","LU2293690082.USD","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641673601","title":"Tempest Therapeutics Appoints Drake Richey and John Yee, Md, Mph to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641673601","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641673601?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:37","pubTimestamp":1780605425,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA5H4Z42:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640047911","title":"Tempest Therapeutics issues unregistered warrant for up to 2,344,828 shares in inducement deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2640047911","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640047911?lang=en_us&edition=fundamental","pubTime":"2026-06-02 18:06","pubTimestamp":1780394785,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics priced an inducement deal tied to existing warrants, issuing a new unregistered warrant in a private placement-style transaction.One holder agreed to cash-exercise existing warrants for 1,172,414 shares at USD 1.73 per share, generating about USD 2 million gross proceeds.In exchange, the investor received a new unregistered warrant for 2,344,828 shares at USD 1.73, exercisable after required Nasdaq stockholder approval.H.C. Wainwright served as placement agent, receiving warrants for 82,069 shares with a USD 2.16 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL2Dwmt0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639067777","title":"Tempest Therapeutics director Simantov resigns from board","url":"https://stock-news.laohu8.com/highlight/detail?id=2639067777","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639067777?lang=en_us&edition=fundamental","pubTime":"2026-05-30 05:02","pubTimestamp":1780088526,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics director Ms. Simantov resigned from the board effective May 23, 2026.The resignation was not tied to any disagreement over the company’s operations, policies, or practices.Her separation agreement leaves her existing stock options and shareholdings unchanged.Her indemnification agreement remains in effect, with related protections continuing for six years from separation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL6THbJk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639622213","title":"Tempest Therapeutics announces exercise of 1,172,414 warrants at reduced $1.73 per share price","url":"https://stock-news.laohu8.com/highlight/detail?id=2639622213","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639622213?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:04","pubTimestamp":1780056268,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics set a deal for immediate cash exercise of warrants for 1,172,414 shares at USD 1.73, cut from USD 3.5.Gross proceeds expected at about USD 2 million; closing expected on or about May 29, 2025.Will issue new unregistered short-term warrants for up to 2,344,828 shares at USD 1.73; exercisable only after stockholder approval.New short-term warrants expire two years from issuance; full cash exercise could raise about USD 4 million.Shares from the existing warrant exercise are registered for resale on an effective Form S-1.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL7rmjHF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","TPST","SG9999014005.SGD","LU0314104364.USD","BK4112","BK4588","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4139","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","BK4585","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637934210","title":"Tempest Therapeutics gets Nasdaq notice for failing $2.5 million equity rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2637934210","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637934210?lang=en_us&edition=fundamental","pubTime":"2026-05-23 05:28","pubTimestamp":1779485338,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics received a Nasdaq notice on May 19, 2026, citing non-compliance with the $2.5 million minimum stockholders’ equity requirement after reporting $822,000 as of March 31, 2026.Nasdaq gave the company 45 days, through July 6, 2026, to submit a plan to regain compliance; an accepted plan could allow up to a 180-day extension to cure the deficiency.Separate Nasdaq notices dated May 22, 2026, flagged board and committee independence shortfalls following director resignations, triggering another requirement to submit a compliance plan within 45 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gatheri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL34Y19R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637934258","title":"Tempest Therapeutics directors Brady, Raab, Pellizzari resign from board","url":"https://stock-news.laohu8.com/highlight/detail?id=2637934258","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637934258?lang=en_us&edition=fundamental","pubTime":"2026-05-23 05:06","pubTimestamp":1779483988,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics disclosed board resignations by Stephen Brady, Michael Raab, and Christine Pellizzari, effective May 22, 2026.The departures were not tied to any disputes over the company’s operations, policies, or practices.Separation agreements provide for a waiver of accrued and unpaid director retainer fees, while leaving existing stock option rights and share ownership unchanged.Indemnification arrangements remain in effect, with underlying protections continuing for six years from separation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Secur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL19YKQR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636425168","title":"Tempest Risk Solutions Appoints David Näslund As CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2636425168","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636425168?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:27","pubTimestamp":1779280063,"startTime":"0","endTime":"0","summary":"May 20 (Reuters) - Tempest Security AB ::*DAVID NSLUND HAS BEEN APPOINTED AS THE NEW CEO OF TEMPEST RISK SOLUTIONS*AVID NSLUND JOINS THE COMPANY FROM HIS ROLE AS CEO OF VERIFIERA AND WILL TAKE UP THE ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nRSDc1M328:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635182729","title":"Tempest net loss widens 155% to $27.7 million in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635182729","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635182729?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:05","pubTimestamp":1778792748,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics posted a wider net loss of USD 27.7 million for quarter ended March 31, 2026, up 155% from a year earlier as operating loss widened to USD 27.72 million, up 153%.Acquired in-process R&D expense rose to USD 22.18 million, while general and administrative costs increased 64% to USD 5.43 million.R&D expense dropped 99% to USD 114,000 due to re-prioritizing efforts toward exploring strategic alternatives initiated in April 2025 and culminating in the February 2026 asset acquisition.Cash and cash equivalents fell to USD 1.8 million as of March 31, 2026, down from USD 7.7 million at Dec. 31, 2025, with management flagging substantial doubt about going-concern status within 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL1JrtB9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725036","title":"Tempest Therapeutics Q1 net loss widens on asset acquisition costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725036","media":"Reuters","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725036?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:31","pubTimestamp":1778790717,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Q1 net loss widens on asset acquisition costsOverviewUS CAR-T therapy developer's Q1 net loss widened due to asset acquisition costsResearch and development expenses fell sharply ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R1AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635258317","title":"Tempest Therapeutics Q1 Operating Income USD -27.719 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635258317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635258317?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:15","pubTimestamp":1778789701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX149052:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635772538","title":"Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635772538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635772538?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:15","pubTimestamp":1778789700,"startTime":"0","endTime":"0","summary":"Announced Cincinnati Children's Applied Gene and Cell Therapy Center  as Lead Manufacturing Partner. Appointed Andrew Fang, Ph.D., as Head of Business Development. BRISBANE, Calif., May 14, 2026  -- Tempest Therapeutics, Inc.  , a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.\"We made strong progress in the first quarter as we continued to execute across our lead program TPST-2003,\" said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. \"We advanced key activities supporting the planned initiation of our U.S. registrational study of TPST-2003 in patients with rrMM, including announcing our lead manufacturing partner AGCTC and taking delivery of the TPST-2003 lentiviral vector, a critical component in the manufacturing of TPST-2003. At the same time, we strengthened our ability to unlock ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","BK4230","PFS","BK4187","IE0031619046.USD","IE00B7SZL793.SGD","BK4022","BK4161","BK4139","EMD","IE00B19Z4B17.USD","LU2065731478.USD","BK4195","TPST","BK4211","CAR","BK4006","IE00B66KJ199.SGD","LU0963586101.USD","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633004451","title":"Tempest Therapeutics Inc  expected to post a loss of 28 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633004451","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633004451?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:24","pubTimestamp":1778246645,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc  expected to post a loss of28cents a share - Earnings Preview Tempest Therapeutics Inc TPST.OQ TPST.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633118225","title":"Tempest says TPST-2003 dual-target CAR-T hits 100% complete response in Phase 1 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2633118225","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633118225?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:10","pubTimestamp":1778065808,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics presented updated early-stage clinical data at ISCT 2026 on TPST-2003, its dual-targeting CAR-T program in relapsed or refractory multiple myeloma plus POEMS syndrome.Results showed all evaluable patients who had not previously received CAR-T therapy achieved complete remission across both ongoing Phase 1 trials.Safety findings remained supportive, with no severe cytokine release syndrome or neurotoxicity reported in REDEEM-1.Dataset expanded to 44 patients treated across three studies, strengthening evidence base for the program.Company plans FDA discussions on starting a US registrational study later in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL18PPck:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4585","IE00BN0W2W23.USD","TPST","NDAQ","SG9999014005.SGD","IE00BN0W2T93.GBP","BK4588","LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU0314104364.USD","BK4139","BK4112","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633992415","title":"Jakarta, Danantara Sign Rp17.4 Trillion Waste-to-Energy Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2633992415","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633992415?lang=en_us&edition=fundamental","pubTime":"2026-05-05 13:30","pubTimestamp":1777959043,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta - The Chief Executive Officer of BPI Danantara, Rosan Roeslani, estimated that the investment for a waste-to-energy  project with a daily capacity of 8,000 tons will reach approximately Rp17.4 trillion, assuming an exchange rate of Rp17,400 per US dollar.\"If its [capacity reaches] 8,000 [tons], the investment is approximately US$1 billion,\" Rosan said at the Coordinating Ministry for Maritime Affairs and Investment office in Jakarta on Monday, May 4, 2026.The Jakarta provincial government has signed a memorandum of understanding with Danantara for the PSEL initiative, agreeing to develop waste-to-energy infrastructure in two locations.","market":"sg","thumbnail":"https://statik.tempo.co/data/2026/04/28/id_1470917/1470917_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/04/28/id_1470917/1470917_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2101923/jakarta-danantara-sign-rp17-4-trillion-waste-to-energy-deal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2101923/jakarta-danantara-sign-rp17-4-trillion-waste-to-energy-deal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516112","title":"Tempest to present TPST-2003 clinical update at ISCT annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516112?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:01","pubTimestamp":1777464069,"startTime":"0","endTime":"0","summary":"Tempest to present updated clinical data on dual-targeting CD19/BCMA CAR-T candidate TPST-2003 at ISCT Scientific Annual Meeting in Dublin, May 6-9, 2026.Oral presentation on REDEEM-1 Phase 1/2a trial scheduled for May 6, 2026 .Poster reception for REDEEM-1 set for May 7, 2026 .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL8fW9KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","BK4139","BK4585","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","LU2210150020.SGD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014039.USD","TPST","LU2210149790.SGD","BK4588","LU2095319765.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629494570","title":"Tempest Therapeutics provides update on development of TPST-2003","url":"https://stock-news.laohu8.com/highlight/detail?id=2629494570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629494570?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:30","pubTimestamp":1776861021,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics (TPST) announced that it has achieved a milestone in the development of TPST-2003, Tempest’s dual-targeting CD19/BCMA CAR-T th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-provides-update-on-development-of-tpst-2003-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-provides-update-on-development-of-tpst-2003-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CAR","BK4022","TPST","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629046835","title":"Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T","url":"https://stock-news.laohu8.com/highlight/detail?id=2629046835","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629046835?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:00","pubTimestamp":1776859200,"startTime":"0","endTime":"0","summary":"Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal developmentTech transfer on track to support","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278911/0/en/Tempest-Announces-Key-Manufacturing-Milestone-for-TPST-2003-Dual-Targeting-CD19-BCMA-CAR-T.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4230","TPST","CAR","BK4022"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tempesttx.com","stockEarnings":[{"period":"1week","weight":-0.0079},{"period":"1month","weight":-0.3152},{"period":"3month","weight":-0.4425},{"period":"6month","weight":-0.5949},{"period":"1year","weight":-0.8228},{"period":"ytd","weight":-0.561}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.012727},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.032927},{"month":3,"riseRate":0.461538,"avgChangeRate":0.000618},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.113004},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.011916},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.117762},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.025247},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.054209},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.059229},{"month":10,"riseRate":0.461538,"avgChangeRate":0.94597},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.081423},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.062561}],"exchange":"NASDAQ","name":"Tempest Therapeutics Inc.","nameEN":"Tempest Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tempest Therapeutics Inc.,TPST,Tempest Therapeutics Inc.股票,Tempest Therapeutics Inc.股票老虎,Tempest Therapeutics Inc.股票老虎国际,Tempest Therapeutics Inc.行情,Tempest Therapeutics Inc.股票行情,Tempest Therapeutics Inc.股价,Tempest Therapeutics Inc.股市,Tempest Therapeutics Inc.股票价格,Tempest Therapeutics Inc.股票交易,Tempest Therapeutics Inc.股票购买,Tempest Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction